Background: Many patients seeking bariatric surgery have a history of mood disorders and are actively prescribed antidepressants. While extensive documentation exists on the impact of weight loss surgery on reductions in cardiac, diabetic, and hypertensive medications, little is known about the impact of bariatric surgery on the use of antidepressant medications.
Methods: A retrospective study of 439 patients who had undergone Roux-en-Y gastric bypass (RYGB) from January 2001 to November 2004 was examined for postoperative changes in the use of antidepressant medications.
Results: After RYGB, 23% of the patients had an increase in their antidepressant use, 40% continued to require the same antidepressant, 18% had a change in antidepressant medication, and only 16% had a decrease or discontinued their antidepressant.
Conclusion: Unlike most medications, antidepressant usage did not decrease in the majority of patients after RYGB. These results highlight the prevalence of antidepressant prescription use in patients before and after RYGB and support the need for the careful monitoring of depressive symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11695-011-0517-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effect of Metabolic Bariatric Surgery on Cardiovascular Risks: A Prospective Study Measuring Antibodies to Apolipoprotein A-1.
Obes Surg
January 2025
Cairo University Hospitals, Cairo, Egypt.
Background: Obesity is a chronic disease associated with other associated medical problems, including atherogenic dyslipidemia. Metabolic bariatric surgery (MBS) has been shown to reduce long-term cardiovascular risk (CVR). Anti-ApoA-1 antibodies (AAA1) are independently associated with cardiovascular disease, which remains a major cause of death in individuals with obesity.
View Article and Find Full Text PDFGlobal, regional, and national burden of primary liver cancer attributable to metabolic risks: an analysis of the Global Burden of Disease Study 1990-2021.
Am J Gastroenterol
January 2025
MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background: The global burden of metabolic diseases is increasing, but estimates of their impact on primary liver cancer are uncertain. We aimed to assess the global burden of primary liver cancer attributable to metabolic risk factors, including high body mass index (BMI) and high fasting plasma glucose (FPG) levels, between 1990 and 2021.
Methods: The total number and age-standardized rates of deaths and disability-adjusted life years (DALYs) from primary liver cancer attributable to each metabolic risk factor were extracted from the Global Burden of Disease Study 1990-2021.
Robot Assisted Cholecystectomy Using the BORNS Simphoni System.
JSLS
January 2025
Attending Consultant Department of Minimal Access, Bariatric and Robotic Surgery, MAX Superspeciality Hospital Vaishali and Patparganj, Delhi National Capital Region, India. (Dr. Ahmed).
Background And Objective: Robotic cholecystectomy has technical advantages of 3D visualization, enhanced instrument maneuverability, and increased precision. Less chance of conversion to open and biliary spillage. This study explores the utilization of the BORNS Simphoni Robotic System for robotic cholecystectomy.
View Article and Find Full Text PDFMyocardial mechanical changes before and after bariatric surgery in individuals with obesity and diabetes: a 1-year follow-up study.
Sci Rep
January 2025
Department of Ultrasound, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, China.
Bariatric surgery may have an effect on myocardial mechanics in individuals with obesity and diabetes. In this study, two-dimensional speckle-tracking echocardiography was applied to evaluate the changes of left ventricular myocardial mechanics in individuals with obesity and diabetes before and after bariatric surgery. A total of 58 individuals with obesity were divided into an obesity-only group (30 patients) and an obesity + diabetes group (28 patients).
View Article and Find Full Text PDFManaging obesity in adults with type 1 diabetes.
Diabetes Res Clin Pract
December 2024
Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1(st) St SW, Rochester, MN 55905, USA; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32224, USA. Electronic address:
As the prevalence of obesity has reached epidemic proportions, its prevalence has also increased among adults living with type 1 diabetes mellitus. Unlike the pathophysiologic relationship between obesity and type 2 diabetes mellitus, the relationship between obesity and type 1 diabetes mellitus, and management of obesity in the setting of type 1 diabetes mellitus, have not been well reviewed. In this article, we discuss the comprehensive management of obesity in adults with type 1 diabetes mellitus, focusing on medical nutrition therapy and adjunct therapies such as weight loss-promoting medications and metabolic/bariatric surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!